As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection.

[2] Known side effects include bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy (PML), a brain infection caused by reactivation of latent JC virus infection.

[2] Due to the risk of PML, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) recommend suspension from the market in the European Union and the United States, respectively.

[5] In April 2009, Genentech Inc. announced a phased voluntary withdrawal of Raptiva from the U.S.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.